Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Issue 1 (28th September 2021)

• Record Type: Journal Article
• Authors: Bastiaansen, Anna E M; de Jongste, Adriaan H C; de Bruijn, Marienke A A M; Crijnen, Yvette S; Schreurs, Marco W J; Verbeek, Marcel M; Dumoulin, Daphne W; Taal, Walter; Titulaer, Maarten J; Sillevis Smitt, Peter A E
• Is Part Of: Neuro-oncology advances. Volume 3:Issue 1(2021)
• Publication Date: 2021-09-28
• Subjects: antibodies -- anti-Hu -- natalizumab -- paraneoplastic neurological syndromes -- treatment; 616.99481
• DOI: 10.1093/noajnl/vdab145
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: Paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS) have a very poor prognosis: more than half of the patients become bedridden and median survival is less than 12 months. Several lines of evidence suggest a pathogenic T cell-mediated immune response. Therefore, we conducted a prospective open-label phase II trial with natalizumab. Methods: Twenty Hu-PNS patients with progressive disease were treated with a maximum of three monthly natalizumab cycles (300 mg). The primary outcome measure was functional improvement, this was defined as at least one point decrease in modified Rankin Scale (mRS) score at the last treatment visit. In addition, treatment response was assessed wherein a mRS score ≤3 after treatment was defined as treatment responsive. Results: The median age at onset was 67.8 years (SD 8.4) with a female predominance ( n = 17, 85%). The median time from symptom onset to Hu-PNS diagnosis was 5 months (IQR 2–11). Most patients had subacute sensory neuronopathy ( n = 15, 75%), with a median mRS of 4 at baseline. Thirteen patients had a tumor, all small cell lung cancer. After natalizumab treatment, two patients (10%) showed functional improvement. Of the remaining patients, 60% had a stable functional outcome, while 30% showed further deterioration. Treatment response was classified as positive in nine patients (45%). Conclusions: Natalizumab may ameliorate the disease course in Hu-PNS, but no superior effects above other reported immunosuppressive and immunomodulatory were observed. More effective treatment modalities are highly needed. Trial registration: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000675-13/NL